Status not kept up to date
Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans
NCT05591053 · Activ Surgical · Updated 21 Feb 2024
- What is being tested
- ActivSight
- For
- Esophagus Cancer; Esophageal Cancer; Esophageal Neoplasms; Esophageal Diseases; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Esophagus SCC; Esophagus Tumor; Esophagus Adenocarcinoma; Esophagus Neoplasm
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 70 people. The full rules are on the registry page.
- Where
- United States (2 sites)
- When
- Starts or started 1 April 2023, ends Jan 2025. Registered 24 Oct 2022.
- Results
- None posted yet.
In the researchers' words
ActivSight™ combines an innovative form factor and proprietary software to deliver precise, objective, real-time visualization of blood flow and tissue perfusion intraoperatively for laparoscope-based surgery. A small adaptor that fits between any existing laparoscope and camera systems and a separate light source placed along any current commercial system will deliver objective real-time tissue perfusion and blood flow information intraoperatively. Primary Objective: To determine the feasibility of ActivSight™ in detecting and displaying tissue perfusion and blood flow in the conduit and foregut anastomoses in esophageal resection/reconstructive surgery. The investigators will compare the precision and accuracy among the naked eye inspection, ICG and LSCI in assessing the vascularity of the conduit.
Sites
- University of Pittsburgh Medical Center - Dept of Cardiothoracic SurgeryPittsburgh, Pennsylvania, United States
- West Penn Hospital / Allegheny Health NetworkPittsburgh, Pennsylvania, United States